Many studies have revealed that in sorafenib-resistant HCC cells, the Akt pathway is highly activated (53–56), and inhibition of Akt can potentially reverse this resistance by shifting autophagy from a role in cellular protection to a mechanism promoting death (53). This evidence concerns the gene AKT1 and hepatocellular carcinoma.